Previous 10 | Next 10 |
Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation of the results for preclinical studies evaluating the administration of ROLONTIS on the same day as chemotherapy in a rodent mo...
Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that Lyndah K. Dreiling, M.D., MBA, has been named Senior Vice President, Clinical Development. “We are excited to welcome Dr. Lyndah Drei...
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at the Jefferies Virtual Healthcare Conference 20...
Image source: The Motley Fool. Spectrum Pharmaceuticals Inc (NASDAQ: SPPI) Q1 2020 Earnings Call May 8, 2020 , 11:30 p.m. ET Operator Continue reading
Spectrum Pharmaceuticals, Inc. (SPPI) Q1 2020 Earnings Conference Call May 7, 2020 16:30 ET Company Participants Robert Uhl - Westwicke ICR Joseph Turgeon - President & CEO Kurt Gustafson - CFO Francois Lebel - Chief Medical Officer Thomas Riga - COO Conference Call Pa...
Spectrum Pharmaceuticals (NASDAQ: SPPI ): Q1 Non-GAAP EPS of -$0.22 beats by $0.05 ; GAAP EPS of -$0.36 misses by $0.01 . More news on: Spectrum Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
BLA for ROLONTIS ® (eflapegrastim) under active FDA review - PDUFA date on October 24, 2020 ROLONTIS same day dosing study initiated Updated Poziotinib strategy implemented to include new dosing regimens Poziotinib ZENITH20 Cohort 3 fully enrolled Management to ...
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2020 financial results and provide a corporate update on Thursday, May 7, 2020 at 4:30 p.m. East...
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced dosing of the first patient in a clinical trial to evaluate the administration of ROLONTIS on the same day as chemotherapy. The trial will evaluate the du...
ZENITH20 Phase 2 clinical trial amended to include new dosing regimens aimed at improving therapeutic index Management to host webcast and conference call today to review data and program strategy at 8:30 a.m. ET Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical compa...
News, Short Squeeze, Breakout and More Instantly...
Spectrum Pharmaceuticals Inc. Company Name:
SPPI Stock Symbol:
NASDAQ Market:
Spectrum Pharmaceuticals Inc. Website:
New York, New York--(Newsfile Corp. - December 14, 2022) - Levi & Korsinsky, LLP notifies investors in Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) of a class action securities lawsuit. The lawsuit on behalf of Spectrum investors has been commenced in the the...
NEW YORK, NY / ACCESSWIRE / December 12, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ:SPPI) and reminds investors of the February 3, 2023 deadline to seek th...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Spectrum To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - December 7, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, i...